BURLINGAME, CA--(Marketwired - June 10, 2014) - RefleXion Medical, a medical device company developing the first biologically-guided radiation therapy system for cancer treatment, announced today that it has appointed David Q. Larkin as Vice President of Engineering. An accomplished engineering leader with over 25 years of experience in the fields of medical robotic systems, mechatronics and control systems, Larkin will be responsible for assembling and leading RefleXion's world class engineering organization and will also oversee all aspects of product design and development.
"David has a passion for developing innovative technologies that ultimately deliver a significant clinical benefit to patients. Time and again he has inspired his engineering teams to overcome challenging technical hurdles during product development and to achieve regulatory clearance for complex medical systems. We believe he is ideally suited for leading our design and development efforts," said Dr. Samuel Mazin, President of RefleXion and inventor of the company's core technology.
Larkin joins RefleXion after a 14 year career at Intuitive Surgical (ISI), where he progressed through roles of increasing responsibility, including, Manager of Systems Analysis, Engineering Director and most recently as Vice President of Engineering. During his tenure at ISI, Larkin brought numerous breakthrough products in robotic assisted minimally-invasive surgery into the clinic, culminating in ISI's next generation, single-port robotic surgery platform. Prior to developing medical robotic systems, Larkin served as President of MotionIO, a networked motion control startup and also as Director of Controls at Adept Technology, a developer of industrial robotic systems. Larkin is a named inventor on 29 patents and holds an MS in both Electrical and Mechanical Engineering from Stanford, as well as ScB in Mechanical Engineering from Brown University.
"I am incredibly excited to join RefleXion and to work with the team in revolutionizing radiation therapy. My broad experience in leading interdisciplinary engineering teams to design and develop complex medical systems is well suited to help RefleXion bring its biologically-guided system to market, for the benefit of cancer patients," said Larkin.
About RefleXion Medical
RefleXion Medical is a privately held medical device company developing the first biologically-guided radiation therapy system for cancer treatment. By leveraging Positron Emission Tomography (PET) in a novel way, RefleXion's patented technology will allow tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. Early validation of RefleXion's technology was funded by the National Cancer Institute at the National Institutes of Health, part of the U.S. Department of Health and Human Services (1R43CA153466-1A1). RefleXion is backed by premier venture capital firms Sofinnova Partners, Pfizer Venture Investments and Venrock.
For more information, visit www.reflexionmedical.com and follow @reflexionmed on Twitter.